Novo Nordisk makes Ozempic and Wegovy, both built on the molecule semaglutide. Eli Lilly makes Mounjaro and Zepbound, both built on tirzepatide. So the question “who makes Ozempic” has a short answer, Novo Nordisk, and the more useful answer is that two companies now own the modern GLP-1 market between them. Their competition shapes which drug you can get, what it costs, and how the trial evidence reads.
Who makes what, and why the naming confuses people
The recurring confusion is that each company sells the same molecule under two names. Semaglutide is Ozempic when approved for type 2 diabetes and Wegovy when approved for chronic weight management. The prescribing information for each is distinct, with different dosing and different labeled uses, which you can confirm on the Ozempic label and the Wegovy label. Lilly runs the same pattern: tirzepatide is Mounjaro for diabetes and Zepbound for weight.
This matters because people ask whether Ozempic and Wegovy are competitors. They are not. They are the same maker’s product aimed at two approved uses. The real rivalry is Novo’s semaglutide against Lilly’s tirzepatide.
How do the two molecules actually differ?
Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on two receptors, GLP-1 and GIP. That mechanistic difference is often used to explain why tirzepatide tends to show larger average weight loss in its own trials, but the trials were run separately against separate comparators. There is no single head-to-head study that settles it cleanly, and presenting the two programs as a direct contest overstates what the data support.
The semaglutide record is well documented. The STEP 3 trial paired the drug with intensive behavioral therapy and showed substantial added weight loss over placebo, reported in the STEP 3 results. STEP 4 tested what happens after the dose is established and continued, described in the STEP 4 maintenance trial. And in one of the few older within-class comparisons, STEP 8 measured weekly semaglutide against daily liraglutide, published as the STEP 8 trial.
Does stopping the drug undo the results?
This is the finding that reframes the whole rivalry. The STEP 1 extension followed people after semaglutide was withdrawn and found that much of the lost weight returned over the following year, along with a partial reversal of cardiometabolic gains, reported in the withdrawal analysis. The practical reading is that these are treatments for a chronic condition, not a short course. That shifts the buying decision from a one-time price to a long-run one, and it applies to both makers’ products equally.
Current practice reflects that. The 2025 obesity pharmacotherapy guideline update, at this reference, treats these agents as long-term therapy, and the parallel work on clinical obesity criteria pushes toward defining who benefits rather than dosing by weight alone.
How does the rivalry compare on the things patients feel?
| Factor | Novo Nordisk | Eli Lilly |
|---|---|---|
| Weight-loss brand | Wegovy (semaglutide) | Zepbound (tirzepatide) |
| Diabetes brand | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
| Receptor action | GLP-1 | GLP-1 and GIP |
| Direct cash program | NovoCare self-pay | LillyDirect self-pay |
Note the last row. The competitive pressure between the two companies did something useful for patients: it produced direct-to-consumer cash channels priced below list. That is a genuine benefit of the rivalry, not marketing gloss.
Where does the rivalry leave your wallet?
Both list prices sit above a thousand dollars a month, and almost no one pays that. What you pay depends on whether your plan covers weight management, whether you qualify for a commercial savings card, or whether you use a manufacturer self-pay program. The competition helped, but it did not make either drug cheap.
Telehealth added a third lane. Consumer platforms like Ro, Hims and Hers, Henry Meds, and physician-supervised services such as formblends.com route people to prescribers and, in some cases, to compounded semaglutide at a flat monthly price. That last part needs a clear caveat, covered next.
Where does compounded medication fit into all this?
Compounded semaglutide is prepared by a compounding pharmacy, not manufactured under either company’s approved application. It is not an FDA-approved product, and it has not been through the process that generated the STEP trial evidence. The FDA has issued specific guidance on medications containing semaglutide that are marketed outside the branded products, and it is worth reading before assuming a compounded version is simply a discount copy.
The honest opinion here: compounded semaglutide can offer a predictable cash price when brand access is blocked, but it trades regulatory assurance for that predictability. For someone who can get Wegovy or Zepbound through coverage or a self-pay program, chasing a compounded version to save money is often not the better bet. That call belongs with a prescriber who knows the case.
So does either company “win”?
For patients, the framing of a winner is mostly beside the point. The tirzepatide programs tend to report larger average weight loss, but tolerance varies person to person, and coverage often decides access before efficacy ever enters the conversation. The rivalry’s real gift is that there are now two credible molecules, two makers competing on price channels, and a growing body of evidence for both. Picking between them is a clinical and financial decision, not a loyalty contest.
Key takeaways
- Novo Nordisk makes Ozempic and Wegovy; both are semaglutide, split by approved use.
- Eli Lilly makes Mounjaro and Zepbound; both are tirzepatide, split the same way.
- Tirzepatide’s trials show larger average loss, but there is no clean head-to-head to crown a winner.
- Weight regain after stopping means these are long-term treatments, which reframes the cost.
- Compounded semaglutide is not FDA-approved and is a different kind of choice than the brands.
Frequently asked questions
Who makes Ozempic and Wegovy?
Novo Nordisk makes both. They share one active molecule, semaglutide. Ozempic is approved for type 2 diabetes and Wegovy for chronic weight management, so the difference is the approved use and dosing, not the company or the drug substance.
Who makes Mounjaro and Zepbound?
Eli Lilly makes both. They share the active molecule tirzepatide. Mounjaro is approved for type 2 diabetes and Zepbound for weight management, again a split by indication rather than by manufacturer.
Is one company’s drug clearly better?
The evidence bases are separate trials, so a clean ranking is not honest. Both molecules produce meaningful weight loss and glucose control. Choice usually turns on tolerance, coverage, and what a prescriber judges fits the case.
Does the rivalry lower what patients pay?
Competition pushed both makers to launch direct cash-pay programs below list price, which helped. But list prices still sit above a thousand dollars a month, and what a person pays depends mostly on coverage and which route they use.
Is compounded semaglutide the same as Ozempic or Wegovy?
No. Compounded versions are prepared by compounding pharmacies and are not FDA-approved products. They may contain the same molecule but have not gone through the approval process behind the branded trial evidence.
